For research use only.
Molecular Weight(MW): 258.23
Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits an E3 ubiquitin ligase, which is a CRBN-DDB1-Cul4A complex.
Selleck's Thalidomide has been cited by 18 publications
4 Customer Reviews
Thalidomide and lenalidomide increase the protein level of WT CRBN. Plasmids expressing FS-CRBN WT were transfected into HEK293T cells and then cells were equally divided into each well of a 6-well plate. The cells were treated with thalidomide (100 µM) or lenalidomide (10 µM) for indicated time.
FASEB Journal, 2015, fj.15-274050. Thalidomide purchased from Selleck.
Murine bone marrow-derived DC (cultured for 4 d) conferred thalidomide (30 μM), PYR-41 (5 μM), or DMSO treatment prior to ovalbumin (50 μg/ml) or PBS pulse. The effects of PYR-41 and thalidomide on cross-presentation were determined by confocal microscope (b). For immunofluorescence observations, cross-presented OVA was stained with red (25-D1.16), EEA1 and Rab7 are all stained with green, and nuclei were counterstained with blue (DAPI). Original magnification, ×600.
J Immunol Res, 2018, 2018:5070573. Thalidomide purchased from Selleck.
Purity & Quality Control
Choose Selective E3 ligase Ligand Inhibitors
|Description||Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits an E3 ubiquitin ligase, which is a CRBN-DDB1-Cul4A complex.|
Thalidomide must be metabolized by the liver to form an epoxide that may be the active teratogenic metabolite.  Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when human monocytes are triggered with lipopolysaccharide and other agonists in culture.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.  Thalidomide acts directly, by inducing apoptosis or G1 growth arrest, in MM cell lines and in patient MM cells that are resistant to melphalan, doxorubicin, and dexamethasone (Dex). Thalidomide enhances the anti-MM activity of Dex and, conversely, are inhibited by interleukin 6.  Thalidomide is a potent costimulator of primary human T cells in vitro, synergizing with stimulation via the T cell receptor complex to increase interleukin 2-mediated T cell proliferation and interferon gamma production. Thalidomide also increases the primary CD8+ cytotoxic T cell response induced by allogeneic dendritic cells in the absence of CD4+ T cells. 
Thalidomide (200 mg/kg) results in an inhibition of the area of vascularized cornea of rabbits that ranged from 30% to 51% in three experiments with a median inhibition of 36%. 
-  D'Amato RJ, et al. Proc Natl Acad Sci U S A, 1994, 91(9), 4082-4085.
-  Sampaio EP, et al. J Exp Med, 1991, 173(3), 699-703.
-  Moreira AL, et al. J Exp Med, 1993, 177(6), 1675-1680.
|In vitro||DMSO||51 mg/mL (197.49 mM)|
|Ethanol||2 mg/mL (7.74 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+1% Tween 80+ddH2O (suspension)
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02956538||Unknown status||Drug: Thalidomide|Drug: placebo(for thalidomide)||Crohn Disease||Sixth Affiliated Hospital Sun Yat-sen University||October 2016||Early Phase 1|
|NCT02966522||Unknown status||Drug: Thalidomide|Drug: Dexamethasone||Cardiac Amyloidosis||Seoul National University Hospital|CW pharmaceutical company||October 2016||Phase 2|
|NCT02778893||Unknown status||Drug: Conmana|Drug: Thalidomide||NSCLC||Henan Provincial People''s Hospital||March 2016||Phase 4|
|NCT01937442||Completed||Drug: Thalidomide Celgene™||Multiple Myeloma||Celgene||November 7 2013||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.